5,425 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by CWA Asset Management Group LLC

CWA Asset Management Group LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,425 shares of the biotechnology company's stock, valued at approximately $1,914,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. Renaissance Technologies LLC increased its holdings in shares of United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock worth $692,748,000 after acquiring an additional 22,978 shares in the last quarter. Geode Capital Management LLC lifted its stake in United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock valued at $391,459,000 after buying an additional 45,566 shares in the last quarter. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares during the period. Dimensional Fund Advisors LP lifted its position in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock valued at $186,656,000 after acquiring an additional 22,683 shares in the last quarter. Finally, Pacer Advisors Inc. increased its holdings in United Therapeutics by 0.9% during the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company's stock worth $203,078,000 after purchasing an additional 4,869 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Argus boosted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Monday, December 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

Insider Activity

In related news, Director Judy D. Olian sold 1,750 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $355.88, for a total transaction of $2,773,016.96. Following the completion of the sale, the chief financial officer now owns 5,884 shares of the company's stock, valued at $2,093,997.92. This trade represents a 56.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 142,422 shares of company stock valued at $53,498,732. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Performance

UTHR traded up $6.94 during trading hours on Tuesday, reaching $362.33. The company's stock had a trading volume of 190,720 shares, compared to its average volume of 245,380. The company's 50-day moving average is $370.53 and its 200-day moving average is $351.34. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market cap of $16.18 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.38 EPS. Equities analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.